GSK Reports Positive Phase 3 Data For Meningococcal Vaccine Candidate
14 March 2023 - 06:53PM
Dow Jones News
By Michael Susin
GSK PLC said Tuesday that data from a Phase 3 study showed that
its vaccine candidate against the bacteria that causes meningitis
and septicaemia has met all primary endpoints.
The pharmaceutical giant said its MenABCWY five-in-one
combination vaccine candidate showed a clinically meaningful immune
response and was well tolerated.
If approved, the vaccine candidate could provide the broadest
meningococcal serogroup coverage and could lead to a simplified
immunization schedule, it added.
GSK said it is working closely with regulators to review the
data and the detailed results will be presented in a
publication.
Invasive meningococcal disease, a major cause of meningitis and
septicaemia, is an uncommon but serious illness that can cause
life-threatening complications or even death, typically amongst
previously healthy children and adolescents, it said.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
March 14, 2023 03:38 ET (07:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024